SCHEMBL3868337

SCHEMBL3868337

Cc1oncc1C(=O)Nc1cc(N2CCN(C)CC2)ccc1C(=O)Nc1n[nH]c2sc(C(=O)O)cc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 2/20 0.45
LYN P07948 2/20 0.45
RAF1 P04049 1/20 0.45
BRAF P15056 1/20 0.45
INSR P06213 15/20 0.45
ALK Q9UM73 15/20 0.45
IGF1R P08069 10/20 0.45
LCK P06239 2/20 0.45
KDR P35968 2/20 0.45
MAPK14 Q16539 1/20 0.45
FLT3 P36888 3/20 0.43
AURKA O14965 3/20 0.41
AURKB Q96GD4 3/20 0.41
FGFR1 P11362 2/20 0.41
PLK4 O00444 1/20 0.41
DAPK3 O43293 1/20 0.41
JAK2 O60674 1/20 0.41
MAP4K4 O95819 1/20 0.41
ABL1 P00519 1/20 0.41
NTRK1 P04629 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1781996 0.89 AURKA (0.54) CSF1RLYNRAF1BRAFINSR
SCHEMBL3866841 0.86 ALK (0.44) INSRALKIGF1RAURKAAURKB
SCHEMBL1779553 0.85 AURKA (0.44) CSF1RLYNRAF1BRAFINSR
SCHEMBL3865316 0.84 INSR (0.48) CSF1RLYNINSRALKIGF1R
SCHEMBL3868170 0.84 IGF1R (0.56) INSRALKIGF1RFLT3AURKA
SCHEMBL15362115 0.83 AURKA (0.46) CSF1RLYNRAF1BRAFINSR
SCHEMBL3866037 0.82 RAB9A (0.43) CSF1RBTK
SCHEMBL3867861 0.82 INSR (0.53) CSF1RLYNINSRALKIGF1R
SCHEMBL3868697 0.82 INSR (0.43) CSF1RLYNINSRALKIGF1R
SCHEMBL1780614 0.82 RAF1 (0.42) CSF1RLYNRAF1BRAFINSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1904503-B1 1H-THIENO[2,3-C]-PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2013-11-06 EP claimed
US-20090149457-A1 1H-Thieno[2,3-c]Pyrazole Compounds Useful as Kinase Inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2009-06-11 US claimed
EP-1904503-A1 1H-THIENO[2,3-C]-PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.r.l. (IT) 2008-04-02 EP claimed
WO-2007009898-A1 1H-THIENO[2,3-C]PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2007-01-25 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149457-A1 1H-Thieno[2,3-c]Pyrazole Compounds Useful as Kinase Inhibitors CCNH, PDK1, MAP3K5 CSF1R 3241/4885LYN 583/4885RAF1 220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.